PreveCeutical Signs Research and Option Agreement with UniQuest

Biotech Investing

PreveCeutical Medical announced it entered into a research and option agreement with UniQuest to research the development of Smart-siRNAs for the treatment of diabetes and obesity.

PreveCeutical Medical (CSE:PREV) announced it entered into a research and option agreement with UniQuest to research the development of Smart-siRNAs for the treatment of diabetes and obesity.
As quoted in the press release:

This will be the third research and option agreement between PreveCeutical and UniQuest.
The Research Program
The four year Research Program, which has a targeted start date of the 1^st day of September, 2017, will be led by UQ researcher and PreveCeutical’s Chief Research Officer, Dr. Harendra Parekh (see PreveCeutical’s news release dated May 17, 2017). The research will be carried out by UQ in collaboration with QIMR Berghofer Medical Research Institute’s Professor Grant Ramm and Murdoch University’s Dr. Rakesh Veedu.
To address the global rise of diabetes and obesity, and in furtherance of PreveCeutical’s preventive health care focus, the Research Program builds on years of multi-disciplinary research and development in diabetes and obesity. It will pursue a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue targeted bio-responsive gene delivery systems will be accompanied by systematic evaluation towards gene and protein-silencing in appropriate cell and animal models of obesity and diabetes, to be undertaken in multiple phases.

Click here to read the full press release.

Source: globenewswire.com

diabetes gene therapy health health care medical research Biotech Investing